Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned
Takeda Pharmaceutical Co. Ltd. has licensed exclusive rights to sell AMAG Pharmaceuticals Inc.'s (anemia, cardiovascular, and oncology) intravenous Feraheme (ferumoxytol) for all indications in Europe, Canada, India, Turkey, the Commonwealth of Independent States, and Asia Pacific countries excluding China (where 3SBio already has rights), Japan, and Taiwan.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com